diabetes

Pharmalot Ed Silverman and John Wilkerson

STAT Plus: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs

Biotech Annalisa Merelli

STAT Plus: What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today

Health Andrew Joseph

Type 2 diabetes prevention programs can work at large scale, study finds

Health Anika Nayak

Fresh produce access boosts health outcomes among diabetes patients and those on Medicaid in recent studies

Pharma Elaine Chen

STAT Plus: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation

Health tech Katie Palmer

STAT Plus: Patients loved Carbon Health’s diabetes program. That couldn’t save it

D.C. Diagnosis Rachel Cohrs Zhang

Medicare eligibility is tripping up the GOP presidential candidates

Politics Sarah Owermohle

STAT Plus: Senator floats new models to manage costs of weight loss drugs like Ozempic

Pharma Elaine Chen and Damian Garde

STAT Plus: Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound

Health Katherine MacPhail

Why preventative care is such a tough sell in the U.S., according to chronic disease experts

First Opinion David Panzirer

Insulin is increasingly affordable in the U.S. What about the rest of the world?

Exclusive Megan Molteni

STAT Plus: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse

Health tech Mario Aguilar

STAT Plus: Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag

Health Nicholas St. Fleur

‘What I’m most proud of’: Nick Jonas talks about managing diabetes, his career, and building community

The Obesity Revolution Megan Molteni and Elaine Chen

GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?

The Obesity Revolution Elaine Chen and Megan Molteni

STAT Plus: The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she’s been edged out of the story

Health tech Lizzy Lawrence

STAT Plus: FDA panel votes against GLP-1 therapy from former diabetes unicorn Intarcia

Health tech Lizzy Lawrence

STAT Plus: As competition looms, Insulet sues a rival for allegedly stealing trade secrets on diabetes tech

Biotech Damian Garde, Andrew Joseph, and Elaine Chen

STAT Plus: What to know about this summer’s landmark Wegovy heart health study

Exclusive Nicholas Florko

STAT Plus: Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic

Health tech Lizzy Lawrence

STAT Plus: Dexcom CEO on strategy for bringing continuous glucose monitoring to type 2 diabetes patients

Health Elaine Chen

Stop taking Ozempic before surgery, anesthesiologist group recommends

Biotech Andrew Joseph

STAT Plus: U.K. agency declines to recommend Eli Lilly’s Mounjaro for type 2 diabetes

Health Elaine Chen

STAT Plus: Ozempic 3.0? Lilly’s ‘triple-G’ drug shows biggest weight loss yet in mid-stage trial

Health tech Katie Palmer

STAT Plus: Does DIY still have a place in diabetes care? 

Biotech Jason Mast

STAT Plus: Two type 1 diabetes patients now freed from insulin shots with cell therapy, Vertex reports

Health Elaine Chen

STAT Plus: Lilly’s obesity pill cuts 15% of weight at highest dose in mid-stage trial

Health Elaine Chen

Diabetes will be ‘a defining disease of this century’ as global cases are set to surpass one billion by 2050

Biotech Elaine Chen

STAT Plus: Akero’s NASH drug combined with Ozempic cut liver fat in small study